Haemonetics(HAE)
$120.54-1.82 (-1.49%)
HAE
Haemonetics financials statements
$120.54
At close:-1.82 (-1.49%)
Want to see HAE full AI Analyst Report?
Haemonetics (HAE) Ratios
452 Followers
Haemonetics Ratios
HAE's free cash flow for Q2 2027 was $118.89M. For the 2027 fiscal year, HAE's free cash flow was decreased by $-9.21M and operating cash flow was $128.10M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.95 | 1.62 | 2.56 | 3.06 | 1.71 |
| Quick Ratio | 1.87 | 0.99 | 1.50 | 2.03 | 1.05 |
| Cash Ratio | 0.87 | 0.53 | 0.60 | 1.13 | 0.59 |
| Solvency Ratio | 0.13 | 0.17 | 0.17 | 0.18 | 0.12 |
| Operating Cash Flow Ratio | 1.04 | 0.31 | 0.61 | 1.08 | 0.39 |
| Short-Term Operating Cash Flow Coverage | 58.47 | 0.60 | 17.77 | 23.17 | 0.80 |
| Net Current Asset Value | $ -764.73M | $ -695.14M | $ -466.73M | $ -347.11M | $ -354.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.51 | 0.50 | 0.37 | 0.40 | 0.42 |
| Debt-to-Equity Ratio | 1.54 | 1.49 | 0.84 | 0.94 | 1.04 |
| Debt-to-Capital Ratio | 0.61 | 0.60 | 0.46 | 0.48 | 0.51 |
| Long-Term Debt-to-Capital Ratio | 0.60 | 0.53 | 0.45 | 0.48 | 0.43 |
| Financial Leverage Ratio | 3.01 | 2.99 | 2.29 | 2.37 | 2.48 |
| Debt Service Coverage Ratio | 7.05 | 0.99 | 11.23 | 8.56 | 0.74 |
| Interest Coverage Ratio | 8.41 | 22.76 | 12.67 | 10.67 | 4.72 |
| Debt to Market Cap | 0.48 | 0.39 | 0.19 | 0.18 | 0.24 |
| Interest Debt Per Share | 26.56 | 24.53 | 16.19 | 15.37 | 15.63 |
| Net Debt to EBITDA | 3.65 | 2.58 | 2.13 | 1.91 | 2.72 |
| Profitability Margins | |||||
| Gross Profit Margin | 55.74% | 57.21% | 54.38% | 53.30% | 53.44% |
| EBIT Margin | 11.75% | 18.16% | 15.80% | 14.31% | 10.59% |
| EBITDA Margin | 20.12% | 26.16% | 22.57% | 21.56% | 19.30% |
| Operating Profit Margin | 18.10% | 16.30% | 12.60% | 13.35% | 8.13% |
| Pretax Profit Margin | 9.60% | 15.58% | 11.60% | 12.10% | 6.41% |
| Net Profit Margin | 7.29% | 12.32% | 8.98% | 9.87% | 4.37% |
| Continuous Operations Profit Margin | 7.29% | 12.32% | 8.98% | 9.87% | 4.37% |
| Net Income Per EBT | 76.00% | 79.07% | 77.41% | 81.61% | 68.17% |
| EBT Per EBIT | 53.04% | 95.61% | 92.10% | 90.62% | 78.80% |
| Return on Assets (ROA) | 4.06% | 6.84% | 5.35% | 5.96% | 2.33% |
| Return on Equity (ROE) | 12.22% | 20.43% | 12.25% | 14.11% | 5.79% |
| Return on Capital Employed (ROCE) | 11.42% | 11.84% | 8.70% | 9.27% | 5.70% |
| Return on Invested Capital (ROIC) | 8.66% | 8.06% | 6.70% | 7.51% | 3.36% |
| Return on Tangible Assets | 7.53% | 12.06% | 9.60% | 9.67% | 4.01% |
| Earnings Yield | 3.82% | 5.27% | 2.73% | 2.75% | 1.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.15 | 6.71 | 6.34 | 6.52 | 6.23 |
| Payables Turnover | 11.56 | 8.69 | 8.14 | 8.54 | 7.92 |
| Inventory Turnover | 1.93 | 1.59 | 1.88 | 2.10 | 1.58 |
| Fixed Asset Turnover | 4.36 | 4.79 | 3.57 | 3.76 | 3.84 |
| Asset Turnover | 0.56 | 0.56 | 0.60 | 0.60 | 0.53 |
| Working Capital Turnover Ratio | 2.93 | 3.30 | 2.65 | 2.81 | 2.64 |
| Cash Conversion Cycle | 217.16 | 241.25 | 206.64 | 186.66 | 243.79 |
| Days of Sales Outstanding | 59.33 | 54.36 | 57.60 | 55.95 | 58.57 |
| Days of Inventory Outstanding | 189.39 | 228.89 | 193.89 | 173.46 | 231.29 |
| Days of Payables Outstanding | 31.56 | 42.00 | 44.84 | 42.75 | 46.07 |
| Operating Cycle | 248.73 | 283.24 | 251.48 | 229.41 | 289.86 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.22 | 3.61 | 3.58 | 5.38 | 3.37 |
| Free Cash Flow Per Share | 5.52 | 2.83 | 2.28 | 3.21 | 1.48 |
| Dividend Paid and CapEx Coverage Ratio | 8.95 | 4.63 | 2.74 | 2.48 | 1.78 |
| Capital Expenditure Coverage Ratio | 8.95 | 4.63 | 2.74 | 2.48 | 1.78 |
| Operating Cash Flow Coverage Ratio | 0.24 | 0.15 | 0.22 | 0.36 | 0.22 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.13 | 0.14 | 0.23 | 0.17 |
| Free Cash Flow Yield | 10.22% | 4.48% | 2.69% | 3.88% | 2.35% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 26.36 | 19.09 | 36.57 | 36.41 | 74.40 |
| Price-to-Sales (P/S) Ratio | 1.91 | 2.34 | 3.28 | 3.60 | 3.25 |
| Price-to-Book (P/B) Ratio | 3.20 | 3.87 | 4.48 | 5.14 | 4.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.79 | 22.33 | 37.24 | 25.80 | 42.60 |
| Price-to-Operating Cash Flow Ratio | 8.69 | 17.50 | 23.66 | 15.39 | 18.73 |
| Price-to-Earnings Growth (PEG) Ratio | -0.69 | 0.45 | 16.60 | 0.22 | -1.62 |
| Enterprise Value Multiple | 13.14 | 11.51 | 16.68 | 18.59 | 19.55 |
| Enterprise Value | 3.53B | 4.10B | 4.93B | 4.68B | 3.75B |
| EV to EBITDA | 13.14 | 11.51 | 16.68 | 18.59 | 19.55 |
| EV to Sales | 2.65 | 3.01 | 3.76 | 4.01 | 3.77 |
| EV to Free Cash Flow | 13.55 | 28.77 | 42.69 | 28.76 | 49.48 |
| EV to Operating Cash Flow | 12.03 | 22.55 | 27.12 | 17.15 | 21.76 |
| Tangible Book Value Per Share | -6.52 | -4.75 | -0.22 | 1.50 | -0.55 |
| Shareholders’ Equity Per Share | 16.88 | 16.31 | 18.93 | 16.11 | 14.68 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | 0.21 | 0.23 | 0.18 | 0.32 |
| Revenue Per Share | 28.28 | 27.04 | 25.82 | 23.01 | 19.46 |
| Net Income Per Share | 2.06 | 3.33 | 2.32 | 2.27 | 0.85 |
| Tax Burden | 0.76 | 0.79 | 0.77 | 0.82 | 0.68 |
| Interest Burden | 0.82 | 0.86 | 0.73 | 0.85 | 0.61 |
| Research & Development to Revenue | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 |
| SG&A to Revenue | 0.33 | 0.31 | 0.32 | 0.31 | 0.33 |
| Stock-Based Compensation to Revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
| Income Quality | 3.01 | 1.08 | 1.55 | 2.37 | 3.97 |
Currency in USD
